Minimally invasive surgery linked to lower major complication risk, reduced length of stay, decreased transfusion rate.

Cytoreductive nephrectomy merits further consideration in appropriately risk-stratified, surgically fit patients with mRCC.

Deferred cytoreductive nephrectomy is associated with better survival compared with upfront surgery, including among fit patients receiving immunotherapy. Deferred cytoreductive nephrectomy (CN) may ...

A Canadian study recently assessed 709 patients with intermediate- and high-risk synchronous mRCC with or without sarcomatoid features. Most patients had clear cell histology and were treated with ...

Total tumor burden reductions of 10% or more achieved with presurgical systemic therapy significantly decrease mortality risk following cytoreductive nephrectomy. Findings from separate studies ...

PN and RFA offer similar survival for cT1a RCC tumors ≤2 cm, but PN is superior for larger tumors. RFA may be considered for elderly patients with comorbidities, especially for tumors ≤2 cm. PN ...